CAR-Treg Program
Multiple Sclerosis
About PolTREG
PolTREG is a clinical-stage biotech company pioneering T-regulatory cell (TREG) therapies for autoimmune disorders, with a focus on Type 1 Diabetes (T1D) and Multiple Sclerosis (MS). Founded as a spin-off from the Medical University of Gdańsk, it boasts the most advanced pipeline of Treg cell therapies for autoimmunity and is developing next-generation engineered CAR-Tregs. The company is publicly listed on the Warsaw Stock Exchange and is constructing a significant GMP manufacturing facility to support its clinical programs and future CDMO services.
View full company profileAbout PolTREG
PolTREG is a clinical-stage biotech company pioneering T-regulatory cell (TREG) therapies for autoimmune disorders, with a focus on Type 1 Diabetes (T1D) and Multiple Sclerosis (MS). Founded as a spin-off from the Medical University of Gdańsk, it boasts the most advanced pipeline of Treg cell therapies for autoimmunity and is developing next-generation engineered CAR-Tregs. The company is publicly listed on the Warsaw Stock Exchange and is constructing a significant GMP manufacturing facility to support its clinical programs and future CDMO services.
View full company profileTherapeutic Areas
Other Multiple Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| SPU-16 | Silo Pharma | Preclinical |
| Electroceutical® Therapy | Endonovo Therapeutics | Research |
| BTK allosteric inhibitor | Acellera | Pre-clinical |
| CLS12311 | Cellerys | Phase 2 |
| Interferon-beta variants | Heligenics | Pre-clinical |
| G-NK cells | Indapta Therapeutics | Phase 1 |
| MS Biomarker Research | Rune Labs | Research |
| AVT001 | Avotres | Phase 2b |
| Evobrutinib | Merck KGaA | Phase 3 |
| Undisclosed MS Program | Astoria Biologica | Pre-clinical |
| PV-3212 | Provid Pharma | Pre-clinical |
| REBIF (interferon beta-1a) | EMD Serono | Approved |